Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone

Autor: Moncef Belhassen-García, Antonio Sánchez-Puente, Pedro-Ignacio Dorado-Díaz, Amparo López-Bernús, Jesús Sampedro-Gómez, Raúl Azibeiro-Melchor, Edgard Marcano-Millán, Beatriz Rodríguez-Alonso, María-Elisa Sánchez-Barrado, Ignacio Hernández-García, Ignacio Madruga, Guillermo Hernández-Pérez, Cristina Carbonell, Judit García-Aparicio, Laura Burgos, Eugenia López-Sánchez, Carlos Reina, Ana-María Ramón, Laura Cestero-Ramírez, Fátima Boumhir, Daniel Encinas-Sánchez, María Sánchez-Ledesma, Jacinto Herráez, Patricia Araoz, María-José Sánchez-Crespo, Sandra Rodríguez-Rodríguez, Ana-Elisa Rodríguez-Gude, Miguel-Vicente Sánchez-Hernández, Rafael Borrás, Víctor Sagredo-Meneses, Pedro-Luis Sánchez, Miguel Marcos, José-Ángel Martín-Oterino

Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 11, Iss 198, p 198 (2022)
Journal of Clinical Medicine; Volume 11; Issue 1; Pages: 198

Background: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a71977e8089a802b60bac0f38696af1
https://pubmed.ncbi.nlm.nih.gov/35011938